0 rating(s) (0 ø)

Antibody maytansinoid conjugates for cancer treatments. Maytansinoids were conjugated with lorvotuzumab (left) or trastuzumab (middle) via linkers bearing different release mechanisms (Mol Cancer Ther, 2010). Cleavable linkers undergo distinguished metabolism routes than non-cleavable linkers once internalized (right, Bioconjugate Chem, 2011).


All rights reserved

• This video may not be used, copied nor changed without explicit consent of the author.
 - Uploaded at 09.11.2017
The maximum length of a comment is 1000 characters.
The maximum length of an alias is 30 characters.
Please enter a comment.
Please insert a valid comment!